Reaction: Alternative Modalities to Address Antibiotic-Resistant Pathogens

Fabio Bagnoli is discovery project leader of research & development vaccine programs at GSK. He has served as editor of several publications and is the coordinator of an industrial-academic effort on human organotypic models. He holds a PhD from the University of Padova and conducted post-doctoral studies at Stanford University. David Payne is vice president and head of the Antibacterial Discovery Performance Unit at GSK. He is also principle investigator of GSK's partnerships with BARDA and the Defense Threat Reduction Agency. David holds a PhD and DSc from the University of Edinburgh and has authored >200 conference presentations, abstracts, and publications.